These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8739554)

  • 1. Paroxetine treatment and the prolactin response to sumatriptan.
    Wing YK; Clifford EM; Sheehan BD; Campling GM; Hockney RA; Cowen PJ
    Psychopharmacology (Berl); 1996 Apr; 124(4):377-9. PubMed ID: 8739554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic paroxetine treatment on 5-HT1B and 5-HT1D autoreceptors in rat dorsal raphe nucleus.
    Davidson C; Stamford JA
    Neurochem Int; 2000 Feb; 36(2):91-6. PubMed ID: 10676872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSRI treatment decreases prolactin and hyperthermic responses to mCPP.
    Quested DJ; Sargent PA; Cowen PJ
    Psychopharmacology (Berl); 1997 Oct; 133(3):305-8. PubMed ID: 9361338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus.
    Davidson C; Stamford JA
    Brain Res; 1997 Jun; 760(1-2):238-42. PubMed ID: 9237540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission.
    Cowen PJ; Sargent PA
    J Psychopharmacol; 1997; 11(4):345-8. PubMed ID: 9443523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.
    Sargent P; Williamson DJ; Pearson G; Odontiadis J; Cowen PJ
    Psychopharmacology (Berl); 1997 Aug; 132(3):296-302. PubMed ID: 9292630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of 5-HT1D autoreceptors on the modulation of 5-HT release in guinea-pig mesencephalic raphe, hippocampus and frontal cortex.
    el Mansari M; Blier P
    Br J Pharmacol; 1996 Jun; 118(3):681-9. PubMed ID: 8762094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5-HT1D/1B receptor agonist sumatriptan enhances fear of simulated speaking and reduces plasma levels of prolactin.
    de Rezende MG; Garcia-Leal C; Graeff FG; Del-Ben CM
    J Psychopharmacol; 2013 Dec; 27(12):1124-33. PubMed ID: 23325368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
    Goldberg MR; Lowry RC; Musson DG; Birk KL; Fisher A; De Puy ME; Shadle CR
    J Clin Pharmacol; 1999 Feb; 39(2):192-9. PubMed ID: 11563413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sumatriptan does not stimulate PRL and GH secretion in acromegaly.
    Cuttica CM; Sessarego P; Valenti S; Falivene MR; Giusti M; Giordano G
    Minerva Endocrinol; 1995 Jun; 20(2):141-4. PubMed ID: 8531896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine effects of sumatriptan.
    Herdman JR; Delva NJ; Hockney RE; Campling GM; Cowen PJ
    Psychopharmacology (Berl); 1994 Jan; 113(3-4):561-4. PubMed ID: 7862876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine administration failed [corrected] to influence human exercise capacity, perceived effort or hormone responses during prolonged exercise in a warm environment.
    Strachan AT; Leiper JB; Maughan RJ
    Exp Physiol; 2004 Nov; 89(6):657-64. PubMed ID: 15328306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.
    de Jong TR; Pattij T; Veening JG; Waldinger MD; Cools AR; Olivier B
    Psychopharmacology (Berl); 2005 May; 179(2):509-15. PubMed ID: 15719219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women.
    Boeles S; Williams C; Campling GM; Goodall EM; Cowen PJ
    Psychopharmacology (Berl); 1997 Jan; 129(2):179-82. PubMed ID: 9040124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased sensitivity of 5-HT1D receptors in chronic tension-type headache.
    Rainero I; Valfrè W; Savi L; Ferrero M; Del Rizzo P; Limone P; Isaia GC; Gianotti L; Pollo A; Verde R; Benedetti F; Pinessi L
    Headache; 2002 Sep; 42(8):709-14. PubMed ID: 12390633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery.
    Longmore J; Maguire JJ; MacLeod A; Street L; Schofield WN; Hill RG
    Br J Clin Pharmacol; 2000 Feb; 49(2):126-31. PubMed ID: 10671906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjects.
    Brunswick DJ; Goodman DB; O'Reardon JP; Chopra M; Amsterdam JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):477-80. PubMed ID: 15093954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.
    Koran LM; Pallanti S; Quercioli L
    Eur Neuropsychopharmacol; 2001 Apr; 11(2):169-72. PubMed ID: 11313163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.
    Rainero I; Valfrè W; Savi L; Gentile S; Pinessi L; Gianotti L; Arvat E; Ghigo E; Del Rizzo P; Calvelli P; Limone P
    J Endocrinol Invest; 2001 May; 24(5):310-4. PubMed ID: 11407649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.
    Nic Dhonnchadha BA; Ripoll N; Clénet F; Hascoët M; Bourin M
    Psychopharmacology (Berl); 2005 May; 179(2):418-29. PubMed ID: 15821956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.